Table 3

OR of hospital admission related to COVID-19 in patients with AIRD (univariable analysis)

VariableOR95% CIP
Gender, women0.40.18–0.9880.02
Age (years)1.091.05–1.140
Diagnosis (AIRD: one category vs the rest)*
 Rheumatoid arthritis0.570.27–1.200.14
 Inflammatory polyarthritis0.40.07–2.080.27
 Systemic lupus erythematosus0.40.07–2.080.27
 Psoriatic arthritis1.290.25–6.680.7
 Spondyloarthritis0.780.28–2.180.64
 MTCD2.680.47–15.20.26
 Sjogren syndrome1.020.26–4.010.93
Disease duration1.010.96–1.050.67
Smoking habit (active vs none)3.990.40–39.580.23
Comorbidities (yes)
 Hypertension3.641.65–8.060.001
 Dyslipidaemia1.820.77–4.320.17
 Depression0.140.01–1.180.07
 Diabetes mellitus5.151.5–16.80.007
 Heart disease2.90.93–9.090.06
 Vascular disease4.180.81–21.640.09
 Liver disease1.760.37–8.220.47
 Kidney disease1
 Lung disease (ILD/COPD)3.321.17–9.450.02
 Cancer5.40.58–50.10.13
 Venous thrombosis/lung embolism1
 Thyroid disease0.480.15–1.470.2
NSAIDs0.370.15 –0.910.03
Glucocorticoids2.010.97–4.130.05
csDMARDSs
 Methotrexate–leflunomide–azathioprine0.780.38–1.590.49
 Sulfasalazine1.020.26–4.010.97
 Antimalarial agents0.560.23–1.380.21
Ts/bDMARDs0.390.15–1.010.05
 None1
 Anti-TNF agents0.130.03–0.630.01
 Other biologics1.650.46–6.490.46
JAKis1
  • Other biologics: anti-IL-6 (tocilizumab, sarilumab); rituximab (Rtx); anti-IL-17/23; anti-IL-17.

  • *Other categories could not be represented: polymalgia rheumatica, systemic sclerosis, vasculitis, Raynaud phenomenon, polychondritis, Behçet disease, polymyositis, uveitis inflammatory bowel disease, antiphospholipid syndrome, juvenile idiopathic arthritis, autoinflammatory syndromes and sarcoidosis.

  • AIRD, autoimmune inflammatory rheumatic disease; anti-TNF, tumour necrosis factor; csDMARD, Conventional synthetic disease-modifying antirheumatic drug; IL-6, interleukin-6; JAKi, JAK inhibitors; ts/bDMARDs, target synthetic/biologic disease-modifying antirheumatic drug.